TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Myelofibrosis

228 clinical trials

114 active
/
228 total (since 2015)
46
Phase 1 Active
93 total
66
Phase 2 Active
130 total
16
Phase 3 Active
30 total
5
Phase 4 Active
14 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Novartis 4 2 3
Bristol-Myers Squibb 4 2 1
Incyte Corporation 3 1 2
Chengdu Zenitar Biomedical Technology Co., Ltd 3 1 0
Karyopharm Therapeutics Inc 3 0 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2 3 2
AbbVie 2 2 1
Geron Corporation 2 1 0
Swedish Orphan Biovitrum 2 0 0
iOnctura 2 0 0
GSK 2 0 0
R-Pharm International, LLC 2 0 0
Telios Pharma, Inc. 2 0 0
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 1 5 1
Ajax Therapeutics, Inc. 1 0 0
NCT07317700 RECRUITING
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
Chengdu Zenitar Biomedical Technology Co., Ltd n=105
NCT03165734 RECRUITING
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum n=399
NCT06351631 RECRUITING
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Merck Sharp & Dohme LLC n=400
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT07357727 NOT YET RECRUITING
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals n=460
NCT04468984 ACTIVE NOT RECRUITING
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
AbbVie n=330
NCT04603495 ACTIVE NOT RECRUITING
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Novartis Pharmaceuticals n=430
NCT04576156 ACTIVE NOT RECRUITING
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation n=327
NCT04064060 RECRUITING
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene n=665
NCT04562389 ACTIVE NOT RECRUITING
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Karyopharm Therapeutics Inc n=353
NCT06479135 RECRUITING
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Kartos Therapeutics, Inc. n=600
NCT06468033 RECRUITING
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia n=150
NCT04717414 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Celgene n=313
NCT06336733 RECRUITING
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
Assistance Publique - Hôpitaux de Paris n=50
NCT05198960 RECRUITING
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
University Hospital, Brest n=1,308
NCT05283980 ACTIVE NOT RECRUITING
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
Beth Israel Deaconess Medical Center n=62
NCT04551066 TERMINATED
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Incyte Corporation n=252
NCT04551053 TERMINATED
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation n=177
NCT03952039 COMPLETED
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Celgene n=202
NCT04472598 COMPLETED
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
AbbVie n=252
NCT03755518 TERMINATED
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Celgene n=38
NCT03315221 COMPLETED
Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants.
Nutricia Research n=207
NCT06455007 COMPLETED
Propolis as a Treatment Option for Hand Foot and Mouth Disease
Murat Sutcu n=200
NCT06227676 COMPLETED
Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25
Cornell University n=12
NCT04617028 COMPLETED
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=105
NCT04173494 COMPLETED
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Sierra Oncology LLC - a GSK company n=195
NCT04654624 COMPLETED
Child Discomfort and Parental Acceptability of Silver Diamine Fluoride and Alternative Restorative Treatment
Nourhan M.Aly n=80
NCT03229668 COMPLETED
Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations
Saint Savvas Anticancer Hospital n=78
NCT03232021 WITHDRAWN
Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations
Saint Savvas Anticancer Hospital
NCT02598297 TERMINATED
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Novartis Pharmaceuticals n=49

Data: ClinicalTrials.gov